PGEN News and Press, Precigen Inc. From 06/11/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! We’re approaching the end of trading for the week but we’ve got one more day of market coverage to bring you. Of course, we’re starting that off with a look at the biggest pre-m...

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes - Primary analysis data presented at the Federation of Clinical Immunology Societies (FOCIS) 2021 ...

Precigen to Present at the JMP Securities Life Sciences Conference PR Newswire GERMANTOWN, Md ,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to ...

Precigen (PGEN): Q1 GAAP EPS of -$0.09 beats by $0.07.Revenue of $24.5M (-17.8% Y/Y) beats by $6.07M.Cash, cash equivalents, short-term and long-term investments totaled $209.3M.Press Release For further details see: Precigen EPS beats by $0.07, beats on revenue

Precigen Reports First Quarter 2021 Financial Results - Company on track to achieve stated 2021 milestones - - Initiated Phase 2 clinical trial of PRGN-2009 AdenoVerse™ immunotherapy - - Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in pat...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...

Precigen (PGEN) announces that Rick Sterling is stepping down from his position as Chief Financial Officer effective April 2, 2021.The company also said that Sterling is stepping down from his role by mutual agreement, and added that Precigen has commenced an executive search f...

Precigen Announces Departure of Chief Financial Officer - Commences search for new CFO - PR Newswire GERMANTOWN, Md. , March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and c...

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) - Milestone represents the first patient dosed with an OTS AdenoVerse immunotherapy targeting infectious disease - - RRP is a rar...

Precigen (PGEN) announces that the US FDA has granted orphan drug designation ((ODD)) for PRGN-2012, a first-in-class, investigational off-the-shelf ((OTS)) AdenoVerse immunotherapy for recurrent respiratory papillomatosis ((RRP)), a rare, difficult-to-treat and sometimes fatal...